L D Piro
Overview
Explore the profile of L D Piro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saven A, Carrera C, Carson D, Beutler E, Piro L
Leuk Lymphoma
. 2016 Jul;
5 Suppl 1:133-8.
PMID: 27463495
Ninety patients with advanced refractory chronic lymphocytic leukemia (CLL) were treated with 2-chlorodeoxyadenosine (2-CdA) administered either as a 0.1 mg/kg/day 7-day continuous intravenous infusion or as a 0.028 mg to...
2.
Beutler E, Piro L, Saven A, Kay A, McMillan R, Longmire R, et al.
Leuk Lymphoma
. 2016 Jul;
5(1):1-8.
PMID: 27463204
Hereditary adenosine deaminase deficiency results in failure of the lymphocyte development. This occurs because of the accumulation of deoxyadenine nucleotides in cells with high deoxycytidine kinase and low 5'-nucleotidase activity....
3.
Piro L, White C, Grillo-Lopez A, Janakiraman N, Saven A, Beck T, et al.
Ann Oncol
. 1999 Aug;
10(6):655-61.
PMID: 10442187
Background: Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen which has been utilized for therapy of B-cell non-Hodgkin's lymphoma (NHL). A previous clinical trial demonstrated that...
4.
Saven A, Burian C, Koziol J, Piro L
Blood
. 1998 Sep;
92(6):1918-26.
PMID: 9731048
Hairy cell leukemia is a chronic B-cell disorder that follows an indolent, but progressive course. Cladribine (2-chlorodeoxyadenosine) induces complete remissions in the majority of patients after a single course. We...
5.
Meisenberg B, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro L
Bone Marrow Transplant
. 1998 Jun;
21(9):927-32.
PMID: 9613786
High-dose chemotherapy and stem cell rescue is increasingly being delivered in the outpatient setting. Such intensive outpatient management programs have reduced the total hospital length of stay without compromising clinical...
6.
Gollard R, Miller W, Piro L, Saven A
Leuk Lymphoma
. 1998 Mar;
28(1-2):183-5.
PMID: 9498718
Three patients with chronic myelogenous leukemia (CML) in myeloid blast phase received 2-chlorodeoxyadenosine (2-CdA) at 0.7 mg/kg per course over 5 days every 2-4 weeks for 7, 2 and 5...
7.
Krajewski S, Gascoyne R, Zapata J, Krajewska M, Kitada S, Chhanabhai M, et al.
Blood
. 1997 May;
89(10):3817-25.
PMID: 9160689
Immunohistochemical analysis of the apoptosis-effector protease CPP32 (Caspase-3) in normal lymph nodes, tonsils, and nodes affected with reactive hyperplasia (n = 22) showed strong immunoreactivity in the apoptosis-prone germinal center...
8.
Meisenberg B, Miller W, McMillan R, Callaghan M, Sloan C, Brehm T, et al.
J Clin Oncol
. 1997 Jan;
15(1):11-7.
PMID: 8996119
Purpose: A prospective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell rescue (ASCR) in the outpatient setting. Methods: One hundred thirteen consecutive patients underwent 165 cycles...
9.
Saven A, Piro L
Hematol Cell Ther
. 1996 Dec;
38 Suppl 2:S93-101.
PMID: 9137962
2-Chlorodeoxyadenosine (2-CdA) is unique compared with traditional antimetabolites in that it is equally active against dividing and resting lymphocytes, which may be especially important in the treatment of indolent lymphoproliferative...
10.
Lee T, Miller W, Curd J, Piro L, Saven A
Mayo Clin Proc
. 1996 Oct;
71(10):966-8.
PMID: 8820771
Essential mixed cryoglobulinemia is a systemic disorder in which cutaneous vasculitis and frequently glomerulonephritis are associated with cryoprecipitable serum immune complexes. Typically, the treatment regimen consists of plasmapheresis, high-dose corticosteroids,...